Evaxion A/S is preparing to present new immune data for its personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. This event is significant as it underscores the company's advancements in AI-powered immunotherapy solutions, particularly in the treatment of advanced melanoma.
Evaxion A/S, a clinical-stage TechBio company, operates under the Standard Industrial Classification (SIC) of 2836, which pertains to Biological Products, (No Diagnostic Substances). The company trades on the Nasdaq under the ticker EVAX. Recent filings include multiple 6-K forms, with the latest submitted on October 2, 2026, detailing this upcoming presentation.
The filing reveals that Evaxion will present findings from a phase 2 trial involving EVX-01 in combination with Merck's anti-PD-1 therapy, KEYTRUDA®. The press release states, "New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentation." This presentation is scheduled for November 4-8, 2026, in Phoenix, Arizona.
This update may affect various stakeholders, including patients with advanced melanoma, healthcare providers, and investors interested in the evolving landscape of cancer immunotherapies. The data presented could provide insights into the efficacy of personalized vaccines and their potential to enhance treatment outcomes.
Looking ahead, Evaxion is also set to provide a complete three-year clinical update for EVX-01 at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026. This forthcoming presentation is expected to further elaborate on the vaccine's performance and its implications for future treatments.